IGC Pharma’s (IGC) “Buy” Rating Reaffirmed at Ascendiant Capital Markets

Ascendiant Capital Markets restated their buy rating on shares of IGC Pharma (NYSEAMERICAN:IGCFree Report) in a research report report published on Friday morning, Benzinga reports. The firm currently has a $3.25 target price on the construction company’s stock.

Separately, StockNews.com started coverage on shares of IGC Pharma in a report on Monday, May 6th. They set a sell rating for the company.

Read Our Latest Research Report on IGC Pharma

IGC Pharma Trading Up 36.6 %

Shares of NYSEAMERICAN IGC opened at $0.55 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.86 and a current ratio of 1.85. IGC Pharma has a 52-week low of $0.25 and a 52-week high of $0.91. The company has a market capitalization of $36.75 million, a PE ratio of -2.12 and a beta of 1.51.

About IGC Pharma

(Get Free Report)

IGC Pharma, Inc, a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development.

See Also

Receive News & Ratings for IGC Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGC Pharma and related companies with MarketBeat.com's FREE daily email newsletter.